Carlos A. Matos
University of the Algarve
10 Papers
6 Citations
Carlos A. Matos is an academic researcher from University of the Algarve. The author has contributed to research in topics: Gene & Viral vector. The author has an hindex of 2, co-authored 10 publications.
Chat about Author
Papers
Stress granules, RNA-binding proteins and polyglutamine diseases: too much aggregation?
TL;DR: In this paper, the authors discuss the evidence supporting the existence of a link between stress granule functionality and polyglutamine (PolyQ) disorders, by focusing on the biology of stress granules and on the way it can be altered in a PolyQ disease context.
Autophagy in Spinocerebellar ataxia type 2, a dysregulated pathway, and a target for therapy.
Adriana Marcelo,Inês T. Afonso,Ricardo Afonso-Reis,David V. C. Brito,Rafael G. Costa,Ana Rosa,João Alves-Cruzeiro,Benedita Ferreira,Carina Henriques,Rui Jorge Nobre,Carlos A. Matos,Luís Pereira de Almeida,Clévio Nóbrega +12 more
TL;DR: In this paper, the role of autophagy in SCA2 pathogenesis and its suitability as a target for therapeutic intervention was investigated, and the authors developed and characterized a new striatal lentiviral mouse model that resembles several neuropathological hallmarks observed in scinocerebellar ataxia type 2 (SCA2) including formation of aggregates, neuronal marker loss, cell death and neuroinflammation.
27
Gene Therapy Strategies: Gene Augmentation
Clévio Nóbrega,Liliana Mendonça,Carlos A. Matos +2 more
- 01 Jan 2020
TL;DR: As it was already mentioned in the first chapter of this book, but will also be made clear throughout the remaining chapters, the term gene therapy encapsulates different approaches and applications based on the use and delivery of different nucleic acids.
8
Viral Vectors for Gene Therapy
Clévio Nóbrega,Liliana Mendonça,Carlos A. Matos +2 more
- 28 Jun 2020
TL;DR: The non-viral and viral methods were described in the previous chapter, whereas in this chapter the viral vectors used in gene therapy will be explained.
4
Barriers to Gene Delivery
Clévio Nóbrega,Liliana Mendonça,Carlos A. Matos +2 more
- 28 Jun 2020
TL;DR: There are advantages and disadvantages for each of the described vectors, and the choice between them is very much dependent on the target disease/condition.
2